BlackRock
CYTO

BlackRock’s Altamira Therapeutics Ltd CYTO Stock Holding History

BlackRock’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-154
Closed -$67K – 6041
2022
Q1 		$67K Buy
154
+70
+83% +$33.8K ﹤0.01% 5366
2021
Q4 		$61K Buy
84
+3
+4% +$2.01K ﹤0.01% 5375
2021
Q3 		$65K Buy
+81
New +$91.3K ﹤0.01% 5241

Other funds holding CYTO

Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

BlackRock's CYTO Position: Q2 2022 in Review

BlackRock sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2022, closing a stake of 154 shares — an estimated $67K sold.

BlackRock first reported a position in CYTO in Q3 2021 and held it in 3 quarters. The position peaked at $67K in Q1 2022. 12 funds tracked by Wall St. Rank hold CYTO as of Q2 2022.

  • BlackRock reported no remaining Altamira Therapeutics Ltd position as of Q2 2022 after selling out during the quarter.
  • BlackRock sold 154 Altamira Therapeutics Ltd shares in Q2 2022, an estimated $67K.
  • BlackRock first reported a position in Altamira Therapeutics Ltd in Q3 2021 and held it in 3 quarters.
  • BlackRock's Altamira Therapeutics Ltd position peaked at $67K in Q1 2022.
  • 12 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2022.

Based on BlackRock's 13F filing for Q2 2022, filed 12 Aug 2022.